Sixty-six American troops died in Afghanistan in July, making it the deadliest month for U.S. forces in the Afghanistan War thus far, the Washington Post and others reported.
Casualties of the Afghanistan War have recently been tabulated by the Congressional Research Service, including statistics on American forces, of whom around 1100 have been killed, as well as allied forces, and Afghan civilians. Although the three week old CRS report does not include the very latest figures, it provides links to official and unofficial sources of casualty information that are regularly updated. See “Afghanistan Casualties: Military Forces and Civilians,” July 12, 2010.
A number of other noteworthy new CRS reports that have not been made readily available to the public were obtained by Secrecy News, including these (all pdf):
“Terrorist Material Support: An Overview of 18 U.S.C. 2339A and 2339B,” July 19, 2010.
“Terrorist Material Support: A Sketch of 18 U.S.C. 2339A and 2339B,” July 19, 2010.
“Veterans Medical Care: FY2011 Appropriations,” July 27, 2010.
“U.S. Sanctions on Burma,” July 16, 2010.
“U.S.-Australia Civilian Nuclear Cooperation: Issues for Congress,” July 7, 2010.
Sen. John McCain inserted a nice tribute in the Congressional Record on April 28 to CRS analyst Christopher Bolkcom, our friend and former FAS colleague, who died last year. See “Remembering Christopher C. Bolkcom.”
With wildfire risk increasing and the potential for destruction along with it continues to grow nationwide, the Federation of American Scientists (FAS) today joins with other organizations to launch a new coalition, Partners in Wildfire Prevention.
Nuclear weapons budgeting is like agreeing to buying a house without knowing the sales price, the mortgage rate, or the monthly payment.
Employing a living approach to evidence synthesis, disseminated at a national level, is a streamlined way to enable evidence-based decision-making nationwide.
By providing essential funding mechanisms, the Bioeconomy Finance Program will reduce the risks inherent in biotechnology innovation, encouraging more private sector investment.